Eli Lilly Acquires 4E Therapeutics to Target Chronic Pain
Eli Lilly and Company has acquired Austin-based 4E Therapeutics, a move aimed at integrating 4E’s proprietary MNK inhibitor technology into Lilly’s neuroscience portfolio. The deal seeks to fast-track non-opioid treatments for chronic pain by disrupting specific signaling pathways within peripheral sensory neurons rather than the central nervous system.
The acquisition brings 4E’s lead clinical candidate, 4ET1103, into the fold of one of the world's largest pharmaceutical companies. Having already cleared Phase 1 clinical trials with a favorable safety profile, 4ET1103 represents a shift in pain management strategy. By focusing on the MNK-eIF4E signaling pathway, the drug aims to provide relief while circumventing the addictive properties and neurological side effects common to current opioid-based therapies.
For 4E Therapeutics, the transition to Lilly provides the infrastructure necessary to scale clinical development and global commercialization. Co-founder Joe Price noted that the partnership aligns 4E’s research into molecular pain mechanisms with Lilly’s translational capacity. While the financial specifics of the acquisition remain undisclosed, the move underscores a broader industry push to address neuropathic and chronic pain through targeted, non-addictive molecular interventions. Aquilo Partners LP acted as the exclusive financial advisor for 4E, with legal counsel provided by Wilson Sonsini Goodrich & Rosati LLP.
Comments (0)
No comments yet. Be the first!